Hi Lopez From the SITC 2017 abstracts (O41 on pages 108/109), the BMS trial of its IDO1 & Opdivo combo resulted in 11% Grade 3/4 SAEs and another 2% discontinuation from drug toxicity (including a death) from 216 patients. https://higherlogicdownload.s3.amaz...nual Meeting 2017/SITC_2017_Abstract_Book.pdf So it looks like the IV Cavatak/Keytruda combo has a slightly better safety profile (& more importantly, no toxicity-related deaths !) Cheers
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
